Brand Institute

Congratulations to BeiGene on the approval of Brukinsa (zanubrutinib) ブルキンザ by the Ministry of Health, Labour and Welfare (MHLW) of Japan! #BIbrands Brukinsa is an oral Bruton Tyrosine Kinase (BTK) inhibitor approved in Japan for the treatment of Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenström’s Macroglobulinemia (WM), and Lymphoplasmacytic Lymphoma. #naming #branding #MHLWapproval #globalbrands

Congratulations to Humacyte on the FDA approval of Symvess! #BIbrands Symvess is a one-time, single-use product surgically implanted to replace a patient’s damaged blood vessel after a traumatic injury to the extremity. It is the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization (restoration of blood flow) is needed to avoid imminent limb loss, and autologous vein graft is not feasible. #naming #branding #FDAapproval

📢 Introducing "Distinctive Names, Safer Systems" Medication safety starts with the product’s name. In our new four-part blog series, Distinctive Names, Safer Systems, Scott Sawler, Drug Safety Institute’s President of Canadian Regulatory Affairs, dives into the critical role of drug naming in preventing medication errors, focusing on Canada’s leadership in addressing Look-Alike Sound-Alike (LASA) names. From understanding the global risks posed by LASA drug names to uncovering Canada’s innovative testing framework and its real-world impact, this series highlights how distinctive naming systems enhance patient safety and set global benchmarks. In the first blog, "The Hidden Risks of LASA Drug Names," we examine how similar-sounding or looking drug names contribute to medication errors and their profound effects on patient safety worldwide. Learn why creating unique and unmistakable drug names is more than a regulatory requirement—it’s a lifesaving necessity. 📖 Read the full blog here: https://lnkd.in/eeGf4ED4 #naming #branding #regulatory #LASA #Canada

Congratulations to Mesoblast on the FDA approval of Ryoncil (remestemcel-L-rknd), the first-ever FDA-approved mesenchymal stromal cell (MSC) therapy! #BIbrands Ryoncil is an allogeneic bone marrow-derived MSC therapy approved for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months of age and older. #naming #branding #FDAapproval #celltherapy #innovation

Congratulations to Neurocrine Biosciences on the FDA approval of CRENESSITY (crinecerfont)! #BIbrands CRENESSITY is a breakthrough therapy and first-ever FDA-approved treatment developed specifically for people with congenital adrenal hyperplasia (CAH). It is the first new treatment for CAH in 70 years! #naming #branding #pharmaceuticals #FDAapproval 

Congratulations to Pfizer on the recent EMA approval of PENBRAYA (Meningococcal Groups A, B, C, W, and Y Vaccine)! #BIbrands PENBRAYA is a pentavalent (5-in-1) MenABCWY vaccine, offering broad protection against the 5 leading meningococcal serogroups (A, B, C, W, and Y). #naming #branding #EMAapproval #vaccines

Congratulations to Merus N.V. and Partner Therapeutics on the FDA Approval of BIZENGRI® (zenocutuzumab-zbco)! #BIbrands BIZENGRI is a bispecific antibody medicine based on Merus’ highly innovative and proprietary Biclonics® technology platform. It is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic. #naming #branding #FDAapproval #pancreaticcancer

We are pleased to share that Brand Institute and our Nonproprietary Division, part of our Drug Safety Institute subsidiary, successfully partnered on 90 names from the 76th INN (International Nonproprietary Names) Consultation, held March 28–31, 2024. These names have now been published as part of Recommended INN List 92. This achievement represents a pivotal milestone in the naming process, as achieving recommended INN status marks the final stage of review and approval by the INN Expert Committee. Congratulations to all our clients who now have an approved INN for their respective compounds and assets! Click the following link to view the Brand Institute/Drug Safety Institute partnered names from recommended INN List 92: https://lnkd.in/eXxnf5m4 The next INN meeting is expected to be held in October 2025. Historically, the INN Committee has set the deadline for fall Consultations in June, so now is the perfect time to plan for your early phase clinical trial compounds. Beginning a project soon for the June 2025 deadline will result in a global name (approval by INN and USAN – United States Adopted Name) by June 2027. #naming #pharmaceuticals #regulatory #INN

This Thanksgiving, we’re grateful for the trust our clients place in us to help bring their brands to life. Like the perfect holiday meal, great brand names come together with a thoughtful process, a generous helping of creativity, and plenty of collaboration. Wishing all of our followers, clients, team members and friends a joyful Thanksgiving filled with gratitude, special moments—and memorable names worth savoring. Happy Thanksgiving from all of us at Brand Institute! 🍂🦃

Congratulations to Jazz Pharmaceuticals and Zymeworks Inc. on the FDA approval of Ziihera® (zanidatamab-hrii)! #BIbrands Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ Biliary Tract Cancer (BTC) in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial. #naming #branding #FDAapproval #pharmaceuticals #drugapproval